| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8067416 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(1 year, 1 month from now) | |
| US7566714 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(1 year, 1 month from now) | |
| USRE43797 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
Nov, 2024
(1 year, 1 month from now) | |
| US9433624 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(1 year, 1 month from now) | |
| US7612073 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(1 year, 1 month from now) | |
| US8318745 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(1 year, 1 month from now) | |
| US7727987 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(1 year, 1 month from now) | |
|
US7727987 (Pediatric) | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(1 year, 7 months from now) | |
|
US8318745 (Pediatric) | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(1 year, 7 months from now) | |
|
USRE43797 (Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
May, 2025
(1 year, 7 months from now) | |
|
US9433624 (Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(1 year, 7 months from now) | |
|
US8067416 (Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(1 year, 7 months from now) | |
|
US7566714 (Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(1 year, 7 months from now) | |
|
US7612073 (Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
May, 2025
(1 year, 7 months from now) | |
| US8003126 | BIOMARIN PHARM | Stable tablet formulation |
Nov, 2025
(2 years from now) | |
| US7566462 | BIOMARIN PHARM | Stable tablet formulation |
Nov, 2025
(2 years from now) | |
|
US8003126 (Pediatric) | BIOMARIN PHARM | Stable tablet formulation |
May, 2026
(2 years from now) | |
|
US7566462 (Pediatric) | BIOMARIN PHARM | Stable tablet formulation |
May, 2026
(2 years from now) | |
| US9216178 | BIOMARIN PHARM | Dry blend formulation of tetrahydrobiopterin |
Nov, 2032
(9 years from now) | |
|
US9216178 (Pediatric) | BIOMARIN PHARM | Dry blend formulation of tetrahydrobiopterin |
May, 2033
(9 years from now) | |
Kuvan is owned by Biomarin Pharm.
Kuvan contains Sapropterin Dihydrochloride.
Kuvan has a total of 20 drug patents out of which 0 drug patents have expired.
Kuvan was authorised for market use on 19 December, 2013.
Kuvan is available in powder;oral dosage forms.
Kuvan can be used as for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia, to reduce blood phenylalanine (phe) levels in patients with hyperphenylalaninemia (hpa), to reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption, method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia.
The generics of Kuvan are possible to be released after 01 May, 2033.
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2013
Treatment: For reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; To reduce blood phenylalanine (phe) levels in patients with hyperphenylalaninemia (hpa); Method of use for redu...
Dosage: POWDER;ORAL
KUVAN family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic